PROTAC Market Forecast 2036: Targeted Protein Degradation Technology Set to Transform Precision Medicine Landscape - DelveInsight

DelveInsight's "PROTAC Market Forecast, Target Population, Competitive Landscape, and Market Forecast - 2036" report provides a comprehensive analysis of PROTAC technology, historical and forecasted epidemiology, competitive landscape, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Get a Free Sample for the PROTAC Market Report:
https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the PROTAC Market Report

• In October 2025, Arvinas announced new patient-reported outcomes from the VERITAC-2 study, which were selected for presentation at the European Society for Medical Oncology (ESMO) Congress 2025.
• In November 2025, Arvinas presented multiple scientific abstracts highlighting vepdegestrant at the San Antonio Breast Cancer Symposium (SABCS).
• In March 2025, Arvinas and Pfizer announced positive topline results from the Phase III VERITAC-2 trial, demonstrating a statistically significant improvement in progression-free survival in the ESR1-mutant population compared with fulvestrant.
• The PROTAC market is expected to witness significant growth during the forecast period (2026-2036), driven by increasing clinical development, strategic collaborations, and technological advances in targeted protein degradation.
• PROTAC (PROteolysis TArgeting Chimera) technology is emerging as one of the most promising approaches in precision medicine by selectively degrading disease-causing proteins through the ubiquitin-proteasome system instead of merely inhibiting protein activity.
• Several PROTAC molecules are currently progressing through clinical development, including vepdegestrant (ARV-471), luxdegalutamide (ARV-766), ASP3082, DT2216, HP518, ARV-110, and CC-94676.
• Vepdegestrant, jointly developed by Pfizer and Arvinas, is currently being evaluated as monotherapy in the Phase III VERITAC-2 trial and in combination with palbociclib in the Phase III VERITAC-3 study for patients with ER+/HER2- breast cancer.
• The technology continues to evolve through innovations including nano-PROTACs, ligand-modified PROTAC prodrugs, and biomacromolecule-PROTAC conjugates that improve tissue specificity, membrane permeability, and targeted drug delivery.
• The success of PROTACs has accelerated innovation across the broader Targeted Protein Degradation (TPD) field, including emerging modalities such as LYTACs, AUTACs, and ATTECs.
• According to the American Cancer Society (2023), HR+/HER2- breast cancer accounts for approximately 65-70% of all breast cancers, representing one of the major therapeutic opportunities for PROTAC-based therapies.
• According to SEER (2021), approximately 3.39 million men were living with prostate cancer in the United States, highlighting another significant target population for androgen receptor degraders.
• According to the CDC (2019), 142,462 colorectal cancer cases were reported in the United States.
• Key PROTAC Companies include Pfizer, Arvinas, Bristol Myers Squibb, Celgene, Novartis, Astellas Pharma, Hinova Pharmaceuticals, Nurix Therapeutics, Kymera Therapeutics, Sanofi, Dialectic Therapeutics, Accutar Biotech, and others.
• Key PROTAC Therapies include Vepdegestrant (ARV-471), Luxdegalutamide (ARV-766), ARV-110, ASP3082, DT2216, HP518, CC-94676, NX-2127, NX-5948, KT-474, and others.
• The PROTAC market is expected to expand significantly as ongoing clinical trials, technological innovation, strategic collaborations, and increasing investment continue to accelerate the development of next-generation targeted protein degradation therapies.

PROTAC Overview

PROTAC (PROteolysis TArgeting Chimera) is an innovative drug discovery platform that selectively eliminates disease-causing proteins by utilizing the cell's natural ubiquitin-proteasome degradation system. Unlike conventional small-molecule inhibitors that temporarily block protein activity, PROTAC molecules induce the complete degradation of target proteins, providing prolonged therapeutic effects and the potential to overcome treatment resistance.
PROTACs are heterobifunctional molecules composed of a target-binding ligand linked to an E3 ubiquitin ligase recruiter. This design enables the ubiquitination and subsequent degradation of proteins previously considered "undruggable," including KRAS and STAT3.

Researchers classify PROTACs into three primary categories:

• Traditional small-molecule PROTACs
• BioPROTACs
• Hybrid PROTACs

Since entering clinical development in 2019, PROTAC technology has rapidly emerged as one of the most promising therapeutic platforms across oncology and several other disease areas. Numerous candidates are currently being evaluated in Phase I, Phase II, and Phase III clinical trials.

To know more about the PROTAC market outlook, pipeline landscape, clinical development, and competitive analysis, visit:
https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

PROTAC Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends across the seven major markets (7MM) from 2022 to 2036. It evaluates the target patient population for diseases where PROTAC therapies are being developed, including breast cancer, prostate cancer, colorectal cancer, and other solid tumors. The section also analyzes disease burden, patient segmentation, and future treatment opportunities using published literature and expert opinion.

PROTAC Epidemiology Segmentation

• Target patient population for PROTAC therapies
• HR+/HER2- Breast Cancer patient population
• Metastatic Breast Cancer patient population
• Prostate Cancer patient population
• Colorectal Cancer patient population
• Other oncology indications targeted by PROTAC therapies

Download the report to understand which factors are driving the PROTAC target population and future market opportunities @ PROTAC Market Forecast:
https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

PROTAC Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the anticipated adoption of emerging PROTAC therapies expected to enter the market during the forecast period. The analysis evaluates potential market uptake, therapy adoption, clinical positioning, and commercial opportunities for investigational targeted protein degraders.
The report also provides a detailed assessment of pipeline candidates across Phase I, Phase II, and Phase III clinical development. It highlights each therapy's mechanism of action, clinical progress, collaborations, licensing agreements, regulatory milestones, and recent corporate developments that are expected to shape the future PROTAC landscape.

PROTAC Therapies and Key Companies

• Vepdegestrant (ARV-471): Arvinas/Pfizer
• Vepdegestrant + Palbociclib: Arvinas/Pfizer
• ARV-110: Arvinas
• Luxdegalutamide (ARV-766): Arvinas/Novartis
• ASP3082: Astellas Pharma
• DT2216: Dialectic Therapeutics
• HP518: Hinova Pharmaceuticals
• CC-94676 (BMS-986365): Celgene/Bristol Myers Squibb
• NX-2127: Nurix Therapeutics
• NX-5948: Nurix Therapeutics
• KT-474: Kymera Therapeutics/Sanofi

Discover more about therapies expected to capture significant PROTAC market share @ PROTAC Market Forecast:
https://www.delveinsight.com/sample-request/protac-market-forecast?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

PROTAC Market Drivers

• Growing interest in targeted protein degradation as a next-generation therapeutic platform.
• Ability of PROTACs to degrade previously "undruggable" proteins, including KRAS and STAT3.
• Expanding late-stage clinical pipeline across breast cancer, prostate cancer, and other solid tumors.
• Increasing technological advancements including nano-PROTACs, ligand-modified PROTACs, and biomacromolecule conjugates.
• Rising strategic collaborations and licensing agreements among leading biotechnology and pharmaceutical companies.
• Expansion of the broader Targeted Protein Degradation (TPD) field through emerging technologies such as LYTACs, AUTACs, and ATTECs.
• Growing investment in precision oncology and targeted therapeutics.

PROTAC Market Barriers

• High molecular weight affecting oral bioavailability and membrane permeability.
• Complex molecular design requiring extensive structural optimization.
• Challenges associated with pharmacokinetic properties and targeted drug delivery.
• Limited long-term clinical validation as most candidates remain investigational.
• Regulatory and commercialization uncertainties associated with an emerging therapeutic modality.

Scope of the PROTAC Market Report

• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Coverage: 7MM
• Key PROTAC Companies: Pfizer, Arvinas, Bristol Myers Squibb, Celgene, Novartis, Astellas Pharma, Hinova Pharmaceuticals, Nurix Therapeutics, Kymera Therapeutics, Sanofi, Dialectic Therapeutics, Accutar Biotech, and others.
• Key PROTAC Therapies: Vepdegestrant (ARV-471), Luxdegalutamide (ARV-766), ARV-110, ASP3082, DT2216, HP518, CC-94676, NX-2127, NX-5948, KT-474, and others.
• PROTAC Therapeutic Assessment: Emerging targeted protein degradation therapies, clinical pipeline analysis, and competitive landscape.
• PROTAC Market Dynamics: Market drivers and market barriers.
• Competitive Intelligence Analysis: SWOT analysis, competitive benchmarking, market opportunity assessment, pipeline landscape, and strategic collaborations.
• PROTAC Unmet Needs, KOL Views, Analyst Perspectives, Drug Uptake, and Market Access Assessment.

Table of Contents

• Key Insights
• Report Introduction
• PROTAC Executive Summary
• Key Events
• PROTAC Market Overview At A Glance
• Background And Overview
• Target Population
• PROTAC Marketed Drugs
• PROTAC Emerging Drugs
• PROTAC: The 7MM Analysis
• Unmet Needs
• SWOT Analysis
• KOL Views
• Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.